Amarin Corporation plc announced financial results for Q4 and full year 2025, showing improvements in revenue, operating expenses, and net loss. They highlighted strategic initiatives and operating efficiencies that led to market leadership and a long-term partnership to commercialize VAZKEPA in Europe. They also emphasized a significant expansion of the VASCEPA/VAZKEPA knowledge base with 45 publications in 2025.

In Q4 2025, Amarin reported a 21% decrease in total net revenue compared to Q4 2024, along with a 31% reduction in operating expenses. Operating loss improved by 88%, and net loss improved by 97%. The company ended the year with $302.6 million in cash and investments, with no debt, showcasing financial resilience and positive cash flow.

Key financial metrics for Q4 2025 included a 23% decrease in total net revenue, mainly due to declines in product revenue. Operating expenses decreased by 31%, driven by cost optimization initiatives. The company’s restructuring efforts resulted in a significant improvement in operating loss and net loss compared to the previous year, showcasing financial discipline and efficiency.

Amarin’s non-GAAP adjusted net income for Q4 2025 was $4.4 million, a positive turnaround from the previous year. Adjusted for stock-based compensation, restructuring expenses, and other one-time costs, the company demonstrated a strong performance in improving its bottom line. These adjustments reflect a more accurate picture of the company’s core business operations and financial health.

Read more at GlobeNewswire: Amarin Reports Fourth Quarter and Full Year 2025 Financial